maltooctaose: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 10887738 |
| CHEBI ID | 152439 |
| MeSH ID | M0265341 |
| Synonym |
|---|
| glc(a1-4)glc(a1-4)glc(a1-4)glc(a1-4)glc(a1-4)glc(a1-4)glc(a1-4)glc |
| CHEBI:152439 |
| wurcs=2.0/2,8,7/[a2122h-1x_1-5][a2122h-1a_1-5]/1-2-2-2-2-2-2-2/a4-b1_b4-c1_c4-d1_d4-e1_e4-f1_f4-g1_g4-h1 |
| alpha-d-gluco-hexopyranosyl-(1->4)-alpha-d-gluco-hexopyranosyl-(1->4)-alpha-d-gluco-hexopyranosyl-(1->4)-alpha-d-gluco-hexopyranosyl-(1->4)-alpha-d-gluco-hexopyranosyl-(1->4)-alpha-d-gluco-hexopyranosyl-(1->4)-alpha-d-gluco-hexopyranosyl-(1->4)-d-gluco-he |
| 6156-84-9 |
| maltooctaose |
| W-203297 |
| mfcd05865015 |
| (2r,3r,4s,5s,6r)-2-[(2r,3s,4r,5r,6r)-6-[(2r,3s,4r,5r,6r)-6-[(2r,3s,4r,5r,6r)-6-[(2r,3s,4r,5r,6r)-6-[(2r,3s,4r,5r,6r)-6-[(2r,3s,4r,5r,6r)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,3s,4r,5r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihy |
| (2r,3r,4s,5s,6r)-2-{[(2r,3s,4r,5r,6r)-6-{[(2r,3s,4r,5r,6r)-6-{[(2r,3s,4r,5r,6r)-6-{[(2r,3s,4r,5r,6r)-6-{[(2r,3s,4r,5r,6r)-6-{[(2r,3s,4r,5r,6r)-4,5-dihydroxy-2-(hydroxymethyl)-6-{[(2r,3s,4r,5r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy}oxan-3-yl]oxy} |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Both the length and dispensation of these branches are critical in defining the structure, density, and relative bioavailability of the storage polysaccharide." | ( The Structure of Maltooctaose-Bound Bingham, C; Chiou, J; Fawaz, R; Geiger, JH; Gilbert, L; Nayebi, H; Park, SH, 2023) | 1.25 |
| Class | Description |
|---|---|
| oligosaccharide | A compound in which monosaccharide units are joined by glycosidic linkages. The term is commonly used to refer to a defined structure as opposed to a polymer of unspecified length or a homologous mixture. When the linkages are of other types the compounds are regarded as oligosaccharide analogues. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (20.10) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||